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SUMMARY
Experimental studies have suggested an atheroprotective role of interleukin (IL)-5 through the stimulation of natural immunoglobulin M antibody expression. In the present study we show that there are no associations between baseline levels of IL-5 and risk for development of coronary events or stroke during a 15.7 AE 6.3 years follow-up of 696 subjects randomly sampled from the Malmö Diet and Cancer study. However, presence of a plaque at the carotid bifurcation was associated with lower IL-5 and IL-5 deficiency resulted in increased plaque development at sites of oscillatory blood flow in Apoe À/À mice suggesting a protective role for IL-5 in plaque (6) . They are produced by a relatively small subset of B cells called B1 cells that primarily resides in the spleen and the peritoneum (7) . The notion that B1 cells and natural antibodies have atheroprotective functions has gained support from experimental studies showing that transfer of B1 cells in particular reverses the proatherogenic effect of splenectomy and that this effect is dependent on the ability of B1 cells to secrete IgM antibodies (8) (9) (10) . The mechanisms regulating the expression of danger-associated molecular pattern-specific IgM antibodies by B1 cells remains to be fully characterized (11) , but interleukin (IL)-5 released from type 2 innate lymphoid cells (ILC2) has been identified as one important stimuli (11) . The observation that deletion of ILC2 in hypercholesterolemic mice accelerates atherosclerosis adds further support to the notion of an atheroprotective role of natural antibodies produced through activation of the ILC2/B1 immune pathway (12) . There is also evidence from experimental studies that IL-5 plays a critical role in this atheroprotective immune pathway. Selective genetic ablation of ILC2 in LDL receptor-deficient mice accelerates the development of atherosclerosis, which is prevented by reconstitution with wild-type but not IL5 À/À ILC2 (12) . Similar observations were made following reconstitution of irradiated LDL receptor-deficient mice with wild-type, but not IL-5 deficient, bone marrow (13) . Moreover, Zhao et al. (14) found that a macrophage overexpression of IL-5 was associated with increased plasma levels of natural antibodies and attenuation of atherosclerosis.
Despite the strong experimental evidence of an atheroprotective role of IL-5, little is known about its possible importance for development of cardiovascular disease (CVD) in man. In a case-control study comparing 931 subjects with prevalent coronary heart disease and 974 controls, Clarke et al. (15) found that those in the highest tertile of plasma IL-5 had a 50% higher risk for coronary heart disease. This observation is in apparent contrast to the atheroprotective role of IL-5 suggested by experimental studies but could possibly represent activation of protective responses in subjects with prevalent CVD. To resolve this issue, we studied the association between baseline levels of IL-5 (both in plasma and the release from activated leukocytes) and the risk for development of cardiovascular events during a follow-up period of more than 15 years. We also studied the association between IL-5 and carotid atherosclerosis in the study cohort as well as the development of carotid plaques at sites of artificially modified shear stress in Apoe À/À mice with or without IL-5 deficiency.
METHODS STUDY POPULATION. The study population consisted of a random sample (n ¼ 700) recruited from the cardiovascular arm of the Malmö Diet and Cancer study (16) as previously described (17) . Data regarding the incidence of major coronary events (fatal and nonfatal myocardial infarction, coronary artery by-pass grafting, and percutaneous coronary intervention) and stroke between the baseline investigation from 1991 to 1994 and December 31, 2014, were obtained from the Swedish Discharge Registry and the Cause of Death Registry of Sweden. Based on coronary event rate of 14% in the original cohort (n ¼ 6,102), it was calculated that a subsample of 700 subjects would allow identification of a 5% difference in any given biomarker between incident coronary cases and controls with an alpha value of 0.01 and a power of 0.80. The random subsampling of 700 subjects was performed by an investigator not otherwise involved in the present study. Blood pressure, body mass index, cholesterol, smoking, and lipid levels were determined as previously described (18) . Four subjects were excluded due to incomplete data. The study was approved by the Ethics Committee of Lund University and was conducted in accordance with the Helsinki Declaration. All subjects gave written informed consent. Plaque was defined as a focal thickening of the IMT exceeding 1.2 mm and a plaque area >10 mm 2 (19) .
Blood was collected in heparin-containing BD (17, 20, 21) . The animal studies were approved by the Malmoe/ Lund regional ethical committee (Sweden).
SAMPLE PREPARATION AND HISTOLOGIC ANALYSES.
The carotid arteries were fixed in Histochoice Table 1) . They also had higher baseline fasting glucose, hsCRP, and systolic blood pressure as well as lower HDL cholesterol.
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There was no difference in plasma levels of IL-5 between those with and without MACE ( Table 1) . To further investigate a possible association between IL-5 and risk of MACE, we analyzed the release of IL-5 from activated peripheral blood mononuclear cells (PBMCs). These PBMCs were isolated at the baseline investigation and stored at -140 C with more than 95% of the cells remaining viable when thawed 20 years later (24) . The cells were activated by exposure to CD3/CD28 beads for 72 h followed by analysis of IL-5 in the cell culture medium. Again, we found no difference between those with or without MACE ( Table 1) . Because IL-5 levels both in plasma and cell medium were skewed, we categorized IL-5 levels into low, medium, and high using the intervals 0 to 0.50, 0.51 to 1.00, and >1.00 pg/ml, respectively, for plasma and 0, 0.1 to 20.0, and >20.0 pg/ml, respectively, for cell-conditioned medium; these IL-5 categories There were 122 cases of incident stroke during the follow-up period. There was no difference in plasma levels of IL-5, or the release of IL-5 from activated PBMCs, between those with and without incident stroke ( Table 1 ). There were also no associations between IL-5 categories and risk for development of stroke ( Figures 1C and 1D) , and this remained the same when controlling for the same covariates as above in plasma IL-5 levels for total circulating numbers of CD4 þ T cells ( Table 2) . When adjusting for age and sex decreased with age and correlated with hsCRP, but otherwise the IL-5 levels did not correlate significantly with cardiovascular risk factors ( Table 3) .
Plasma levels of IL-5 were inversely related to the number of CD8 þ T cells in the blood, but there were no significant associations with other T cell subsets including the number of Th2 (IL-4 þ /CD4 þ ) cells ( Table 3) . When comparing the release of IL-5 from activated leukocytes, we instead found significant positive associations with both the number of CD4 þ and CD8 þ T cells in the blood ( Table 2) . Finally, we determined the association between IL-5 and 2 different oxidized LDL-specific IgM antibodies and found a weak significant association between IL-5 released from activated leukocytes and IgM against whereas plaques at the distal site become more fibrous (Figure 2A) . IL5 À/À Apoe À/À mice developed larger plaques at the site with oscillatory flow than Apoe À/À mice with intact IL-5 expression. There were no differences in plaque size at the site with low shear, laminar flow ( Figure 2B) . IL-5 deficiency did not affect the macrophage and collagen content in plaques at either site ( Figures 2C and 2D) . Atherosclerosis in the descending aorta, a site where blood flow also is predominantly laminar with high shear stress, was assessed by en face staining with Oil Red O. Again, we found no difference between IL5 À/À Apoe À/À and Apoe À/À mice ( Figure 2E) . IL-5 deficiency did not affect plasma levels of IL-6, monocyte chemotactic protein-1, tumor necrosis factor-a, IL-10, IL-13, and IL-17, suggesting that the IL-5-deficiency has no effect on systemic inflammation (data not shown). It also was without effect on plasma cholesterol and triglyceride levels ( Figures 3A and 3B) . IL-5 is known to stimulate the synthesis of the natural, germline-encoded IgM antibodies that facilitates the removal of certain micro-organisms, apoptotic cells, and oxidized LDL.
In accordance, IL-5-deficient mice had lower levels of IgM against oxidized LDL, whereas there were no differences in IgM against phosphoryl choline or MDA ( Figures 3C to 3E) . The lower levels of IgM against oxidized LDL in IL-5-deficient mice were not associated with reduced accumulation of IgM or an increased presence of apoptotic cells in carotid plaques ( Figures 4A and 4B) .
DISCUSSION
In the present study, we found no association between plasma levels of IL-5 at baseline and the risk for development of coronary events during a follow-up period of more than 15 years. There was also no association between the release of IL-5 from activated leukocytes and the risk of coronary events. Accordingly, IL-5 is likely not a clinically useful marker of Abbreviations as in Table 1 . which are more in accordance with the atheroprotective effects of IL-5 found in experimental studies (12) (13) (14) . In both studies, the inverse association between IL-5 and atherosclerosis was only observed in the carotid bulb, but not in the common carotid artery, suggesting that it may be dependent on the pattern of blood flow. Blood flow in the common carotid artery is laminar, producing a high shear stress that is anti-inflammatory and has an anti-atherogenic FIGURE 2 Continued (A) To induce plaque formation in Apoe À/À and IL5 À/À Apoe À/À mice a cast with a fixed geometry was applied to the right carotid artery generating a laminar, low shear stress proximal to the cast and an oscillatory flow distal to the cast. (B) IL5 À/À Apoe À/À mice developed larger plaques at the site with oscillatory flow than Apoe À/À mice with intact interleukin 5 (IL-5) expression. There were no differences in plaque size at the site with low shear, laminar flow. (C, D) IL-5 deficiency did not affect the macrophage or collagen content in plaques at either site. (E) Atherosclerosis in the descending aorta, a site where blood flow also is predominantly laminar, was assessed by en face staining with Oil Red O. No difference was found between IL5 À/À Apoe À/À and Apoe À/À mice. Graphs are plotted as median with interquartile range. The p values were calculated using the Mann-Whitney U test. There are some limitations of the present study that should be considered. In the clinical study, we only had access to IL-5 values from a single time point (e.g., the baseline investigation). There is no published data on how the plasma level of IL-5 varies over time in the same individual. A study where blood samples were repeatedly drawn from healthy volunteers during a 2-month period found correlations coefficients ranging from 0.6 to 0.9 for IL-1b, IL-6, and IL-8 suggesting that plasma cytokine levels in healthy individuals are relatively stable (31) . Furthermore, it cannot be excluded that the long storage period affected the possibility to correctly analyze plasma IL-5. Finally, the cohort used in the present study may have been too small for identification of associations between IL-5 and cardiovascular risk.
In conclusion, we applied a translational approach to study the role of IL-5 in CVD. We found evidence for a protective role of IL-5 in the development of atherosclerotic plaques at sites of oscillatory blood flow but found no evidence that this was associated with a reduced risk of cardiovascular events.
